S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:KRTX

Karuna Therapeutics (KRTX) Stock Price, News & Analysis

$316.24
+2.27 (+0.72%)
(As of 03/1/2024 ET)
Today's Range
$315.00
$317.00
50-Day Range
$313.42
$320.85
52-Week Range
$158.38
$321.45
Volume
242,648 shs
Average Volume
449,628 shs
Market Capitalization
$12.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$293.92

Karuna Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
7.1% Downside
$293.92 Price Target
Short Interest
Bearish
5.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Karuna Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$8.36 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($11.69) to ($7.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.88 out of 5 stars

Medical Sector

846th out of 952 stocks

Pharmaceutical Preparations Industry

388th out of 433 stocks


KRTX stock logo

About Karuna Therapeutics Stock (NASDAQ:KRTX)

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

KRTX Stock Price History

KRTX Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
1KRTX : Karuna Therapeutics: Q4 Earnings Insights
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Karuna Therapeutics: Getting Sold Short
KRTX Mar 2024 320.000 call
KRTX Mar 2024 260.000 put
KRTX Mar 2024 330.000 call
KRTX Mar 2024 280.000 put
Karuna Therapeutics just downgraded at JPMorgan, here's why
See More Headlines
Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/01/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$293.92
High Stock Price Target
$330.00
Low Stock Price Target
$225.00
Potential Upside/Downside
-7.1%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
16 Analysts

Profitability

Net Income
$-433,680,000.00
Pretax Margin
-66,209.48%

Debt

Sales & Book Value

Annual Sales
$650,000.00
Price / Sales
18,560.86
Book Value
$32.88 per share

Miscellaneous

Free Float
33,112,000
Market Cap
$12.06 billion
Optionable
Optionable
Beta
1.22
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Andrew Craig Miller Ph.D. (Age 42)
    Founder and President of Research & Development
    Comp: $835.4k
  • Dr. Stephen K. BrannanDr. Stephen K. Brannan (Age 68)
    Chief Medical Officer
    Comp: $751.75k
  • Mr. William Meury (Age 56)
    President, CEO & Director
  • Mr. Jason Parker Brown
    Chief Financial Officer
  • Ms. Alexis Smith
    Vice President of Corporate Affairs & Investor Relations
  • Ms. Mia Kelley J.D.
    General Counsel
  • Mr. Frank Truslow
    Senior Vice President of Corporate Development
  • Mr. Jonathan Rosin
    Chief Human Resources Officer
  • Dr. Alan Breier
    Chair of Scientific Advisory Board & Chief Clinical Advisor
  • Dr. Ronald N. Marcus M.D. (Age 66)
    Senior Vice President of Medical














KRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" KRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KRTX, but not buy additional shares or sell existing shares.
View KRTX analyst ratings
or view top-rated stocks.

What is Karuna Therapeutics' stock price target for 2024?

16 Wall Street analysts have issued 1-year price objectives for Karuna Therapeutics' stock. Their KRTX share price targets range from $225.00 to $330.00. On average, they anticipate the company's share price to reach $293.92 in the next twelve months. This suggests that the stock has a possible downside of 7.1%.
View analysts price targets for KRTX
or view top-rated stocks among Wall Street analysts.

How have KRTX shares performed in 2024?

Karuna Therapeutics' stock was trading at $316.51 on January 1st, 2024. Since then, KRTX shares have decreased by 0.1% and is now trading at $316.24.
View the best growth stocks for 2024 here
.

Are investors shorting Karuna Therapeutics?

Karuna Therapeutics saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 2,110,000 shares, an increase of 24.9% from the January 31st total of 1,690,000 shares. Based on an average daily trading volume, of 860,600 shares, the days-to-cover ratio is presently 2.5 days.
View Karuna Therapeutics' Short Interest
.

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KRTX earnings forecast
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings data on Thursday, February, 22nd. The company reported ($3.01) EPS for the quarter, missing analysts' consensus estimates of ($2.65) by $0.36. The business's quarterly revenue was down 100.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.22) EPS.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital International Investors (11.20%), Vanguard Group Inc. (8.55%), Price T Rowe Associates Inc. MD (5.20%), Brown Advisory Inc. (0.88%), Norges Bank (0.87%) and Balyasny Asset Management L.P. (0.84%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends
.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRTX) was last updated on 3/2/2024 by MarketBeat.com Staff